{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:14:25Z","timestamp":1778318065662,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen Nanshan District Health System Science and Technology Major Project","award":["NSZD2023018"],"award-info":[{"award-number":["NSZD2023018"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2019YFA0904200 and 2019YFA0906100"],"award-info":[{"award-number":["2019YFA0904200 and 2019YFA0906100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Fundamental Research Program (Natural Science Foundation)-Key Basic Research Project","award":["JCYJ20241202125200001"],"award-info":[{"award-number":["JCYJ20241202125200001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171464"],"award-info":[{"award-number":["32171464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Medical Research Fund","award":["B2402027"],"award-info":[{"award-number":["B2402027"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although CD19 and CD22 chimeric antigen receptor (CAR-T) cell therapies have demonstrated encouraging clinical responses in patients with B-cell lymphoma, over 50% of patients ultimately experience disease progression due to frequent antigen escape. The development of CD19\/CD22 dual-target CAR-T cells holds promise for overcoming this limitation; however, their clinical application is currently challenging because of insufficient targeting of CD22.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we engineered CD19\/CD22 BS Loop CAR-T cells with an enhanced targeting efficacy for CD22 and assessed their safety and effectiveness in patients with relapsed\/refractory diffuse large B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the five patients who received CD19\/CD22 bispecific Loop CAR-T-cell therapy (1.6\u00a0\u00d7\u00a0106\/kg) from December 2023 to May 2024, four patients (80%) achieved complete remission (CR), and one patient (20%) maintained a stable disease status 1 month after infusion. The expansion of the CD19\/CD22 Beta-stranded (BS) Loop CAR-T cells was effective in vivo and detectable in the peripheral blood. All patients experienced only Grade 0\u20131 cytokine release syndrome without any observed neurotoxicity. With the follow-up extended to May 2025 (lasting for at least 1\u00a0year), three patients experienced disease progression and eventually died, while the remaining two patients remained in CR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD19\/CD22 BS Loop CAR-T-cell therapy exhibits potent antilymphoma activity while addressing the challenges associated with designing CAR-T cells that are equally potent against two antigens. This treatment may represent a safe and effective unique immunotherapeutic strategy for lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/abt\/tbaf027","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:56:52Z","timestamp":1763470612000},"page":"24-37","source":"Crossref","is-referenced-by-count":0,"title":["Unique loop-structured CD19\/CD22 bispecific CAR-T-cell therapy for patients with relapsed\/refractory diffuse large B-cell lymphoma: an observational study"],"prefix":"10.1093","volume":"9","author":[{"given":"Shuhong","family":"Li","sequence":"first","affiliation":[{"name":"State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School , Shenzhen 518055 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjiang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School , Shenzhen 518055 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shenzhen Cell Valley Biomedical Co., Ltd , Shenzhen 518118 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[{"name":"National Engineering Research Center for Foundational Technologies for CGT Industry , Shenzhen 518055 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Shenzhen Cell Valley Biomedical Co., Ltd , Shenzhen 518118 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-7757","authenticated-orcid":false,"given":"Yu J","family":"Cao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School , Shenzhen 518055 ,","place":["China"]},{"name":"Shenzhen Bay Laboratory, Institute of Chemical Biology , Shenzhen 518132 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Nanshan Hospital of Shenzhen University , Shenzhen 518052 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026050904364585200_ref1","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"2026050904364585200_ref2","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"key":"2026050904364585200_ref3","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"2026050904364585200_ref4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026050904364585200_ref5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026050904364585200_ref6","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"2026050904364585200_ref7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2026050904364585200_ref8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"2026050904364585200_ref9","article-title":"A novel loop-structure-based bispecific CAR that targets CD19 and CD22 with enhanced therapeutic efficacy against B-cell malignances","volume":"16","author":"Zhao","journal-title":"Protein Cell"},{"key":"2026050904364585200_ref10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jconrel.2023.04.048","article-title":"Multi-targeted immunotherapeutics to treat B cell malignancies","volume":"358","author":"Gambles","year":"2023","journal-title":"J Control Release"},{"key":"2026050904364585200_ref11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"2026050904364585200_ref12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am J Hematol"},{"key":"2026050904364585200_ref13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026050904364585200_ref14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-019-0741-6","article-title":"Haploidentical CD19\/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Jia","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026050904364585200_ref15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"2026050904364585200_ref16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol Ther"},{"key":"2026050904364585200_ref17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"2026050904364585200_ref18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2026050904364585200_ref19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2026050904364585200_ref20","doi-asserted-by":"publisher","first-page":"112174","DOI":"10.1016\/j.intimp.2024.112174","article-title":"Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: a case report","volume":"134","author":"Zhong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026050904364585200_ref21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026050904364585200_ref22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"2026050904364585200_ref23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026050904364585200_ref24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026050904364585200_ref25","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","article-title":"A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"key":"2026050904364585200_ref26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"2026050904364585200_ref27","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2026050904364585200_ref28","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026050904364585200_ref29","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood.2022018598","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"2026050904364585200_ref30","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"2026050904364585200_ref31","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.jbc.2021.100966","article-title":"Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22","volume":"297","author":"Ere\u00f1o-Orbea","year":"2021","journal-title":"J Biol Chem"},{"key":"2026050904364585200_ref32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2026050904364585200_ref33","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"2026050904364585200_ref34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"key":"2026050904364585200_ref35","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u2009cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B\u2009cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat Med"},{"key":"2026050904364585200_ref36","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"2026050904364585200_ref37","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2026050904364585200_ref38","first-page":"578","article-title":"Long-term follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"key":"2026050904364585200_ref39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"2026050904364585200_ref40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbaf027\/65407618\/tbaf027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/1\/24\/67314466\/tbaf027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/1\/24\/67314466\/tbaf027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:36:52Z","timestamp":1778315812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/1\/24\/8329210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,14]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbaf027","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,20]]}}}